Novartis secures first-of-a-kind haematology approval
A novel Factor B inhibitor of the immune system’s complement pathway has been approved for paroxysmal nocturnal haemoglobinuria (PNH).
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
